Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Tadakazu Hisamatsu; Reiko Kunisaki; Shiro Nakamura; Tomoyuki Tsujikawa; Fumihito Hirai; Hiroshi Nakase; Kenji Watanabe; Kaoru Yokoyama; Masakazu Nagahori; Takanori Kanai; Makoto Naganuma; Hirofumi Michimae; Akira Andoh; Akihiro Yamada; Tadashi Yokoyama; Noriko Kamata; Shinji Tanaka; Yasuo Suzuki; Toshifumi Hibi; Mamoru Watanabe

doi:10.5217/ir.2018.16.3.494

Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial

Tadakazu Hisamatsu^*, Reiko Kunisaki, Shiro Nakamura, Tomoyuki Tsujikawa, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Kaoru Yokoyama, Masakazu Nagahori, Takanori Kanai, Makoto Naganuma, Hirofumi Michimae, Akira Andoh, Akihiro Yamada, Tadashi Yokoyama, Noriko Kamata, Shinji Tanaka, Yasuo Suzuki, Toshifumi Hibi, Mamoru Watanabe

^*Corresponding author for this work

Internal Medicine （3）

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Original language	English
Pages (from-to)	494-498
Number of pages	5
Journal	Intestinal Research
Volume	16
Issue number	3
DOIs	https://doi.org/10.5217/ir.2018.16.3.494
State	Published - 2018

ASJC Scopus subject areas

Gastroenterology

Access to Document

10.5217/ir.2018.16.3.494

Cite this

Hisamatsu, T., Kunisaki, R., Nakamura, S., Tsujikawa, T., Hirai, F., Nakase, H., Watanabe, K., Yokoyama, K., Nagahori, M., Kanai, T., Naganuma, M., Michimae, H., Andoh, A., Yamada, A., Yokoyama, T., Kamata, N., Tanaka, S., Suzuki, Y., Hibi, T., & Watanabe, M. (2018). Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial. Intestinal Research, 16(3), 494-498. https://doi.org/10.5217/ir.2018.16.3.494

@article{02cde7f3902b4b4bb407b14affaaf682,

title = "Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial",

author = "Tadakazu Hisamatsu and Reiko Kunisaki and Shiro Nakamura and Tomoyuki Tsujikawa and Fumihito Hirai and Hiroshi Nakase and Kenji Watanabe and Kaoru Yokoyama and Masakazu Nagahori and Takanori Kanai and Makoto Naganuma and Hirofumi Michimae and Akira Andoh and Akihiro Yamada and Tadashi Yokoyama and Noriko Kamata and Shinji Tanaka and Yasuo Suzuki and Toshifumi Hibi and Mamoru Watanabe",

note = "Funding Information: This work was funded by EA Pharma Co., Ltd. and undertaken by the Japanese Society for Inflammatory Bowel Disease.",

year = "2018",

doi = "10.5217/ir.2018.16.3.494",

language = "英語",

volume = "16",

pages = "494--498",

journal = "Intestinal Research",

issn = "1598-9100",

publisher = "Korean Association for the Study of Intestinal Diseases",

number = "3",

}

Hisamatsu, T, Kunisaki, R, Nakamura, S, Tsujikawa, T, Hirai, F, Nakase, H, Watanabe, K, Yokoyama, K, Nagahori, M, Kanai, T, Naganuma, M, Michimae, H, Andoh, A, Yamada, A, Yokoyama, T, Kamata, N, Tanaka, S, Suzuki, Y, Hibi, T & Watanabe, M 2018, 'Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial', Intestinal Research, vol. 16, no. 3, pp. 494-498. https://doi.org/10.5217/ir.2018.16.3.494

TY - JOUR

T1 - Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab

T2 - CERISIER trial

AU - Hisamatsu, Tadakazu

AU - Kunisaki, Reiko

AU - Nakamura, Shiro

AU - Tsujikawa, Tomoyuki

AU - Hirai, Fumihito

AU - Nakase, Hiroshi

AU - Watanabe, Kenji

AU - Yokoyama, Kaoru

AU - Nagahori, Masakazu

AU - Kanai, Takanori

AU - Naganuma, Makoto

AU - Michimae, Hirofumi

AU - Andoh, Akira

AU - Yamada, Akihiro

AU - Yokoyama, Tadashi

AU - Kamata, Noriko

AU - Tanaka, Shinji

AU - Suzuki, Yasuo

AU - Hibi, Toshifumi

AU - Watanabe, Mamoru

N1 - Funding Information: This work was funded by EA Pharma Co., Ltd. and undertaken by the Japanese Society for Inflammatory Bowel Disease.

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85051246139&partnerID=8YFLogxK

U2 - 10.5217/ir.2018.16.3.494

DO - 10.5217/ir.2018.16.3.494

M3 - 学術論文

AN - SCOPUS:85051246139

SN - 1598-9100

VL - 16

SP - 494

EP - 498

JO - Intestinal Research

JF - Intestinal Research

IS - 3

ER -